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Glycomimetic-based pharmacological chaperones
for lysosomal storage disorders: lessons from
Gaucher, GM1-gangliosidosis and Fabry diseases
Elena M. Sa´nchez-Ferna´ndez,a Jose´ M. Garcı´a Ferna´ndez*b and
Carmen Ortiz Mellet*a
Lysosomal storage disorders (LSDs) are often caused by mutations that destabilize native folding and
impair the traﬃcking of enzymes, leading to premature endoplasmic reticulum (ER)-associated degradation,
deficiencies of specific hydrolytic functions and aberrant storage of metabolites in the lysosomes.
Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are available for a few of these
conditions, but most remain orphan. A main diﬃculty is that virtually all LSDs involve neurological
decline and neither proteins nor the current SRT drugs can cross the blood–brain barrier. Twenty years
ago a new therapeutic paradigm better suited for neuropathic LSDs was launched, namely pharmaco-
logical chaperone (PC) therapy. PCs are small molecules capable of binding to the mutant protein at the
ER, inducing proper folding, restoring trafficking and increasing enzyme activity and substrate processing
in the lysosome. In many LSDs the mutated protein is a glycosidase and the accumulated substrate is
an oligo- or polysaccharide or a glycoconjugate, e.g. a glycosphingolipid. Although it might appear
counterintuitive, substrate analogues (glycomimetics) behaving as competitive glycosidase inhibitors are
good candidates to perform PC tasks. The advancements in the knowledge of the molecular basis of
LSDs, including enzyme structures, binding modes, trafficking pathways and substrate processing
mechanisms, have been put forward to optimize PC selectivity and efficacy. Moreover, the chemical versatility
of glycomimetics and the variety of structures at hand allow simultaneous optimization of chaperone and
pharmacokinetic properties. In this Feature Article we review the advancements made in this field in the last
few years and the future outlook through the lessons taught by three archetypical LSDs: Gaucher disease,
GM1-gangliosidosis and Fabry disease.
Introduction
Lysosomal storage disorders (LSDs) are a clinically heterogeneous
group of more than 40 inherited orphan conditions, with an
overall prevalence estimated to be 1 : 1500–1 : 7000 live births,
sharing a common pathobiochemical leitmotiv: a genetic defect
in the genes that encode specific lysosomal enzymes leading to
the storage of complex non-metabolized molecules in the lyso-
some.1 Substrate accumulation then results in chronic and
progressive clinical syndromes that often display a wide spectrum
of abnormalities that are unique to each LSD. Consequently, the
primary target of any therapeutic strategy towards LSDs, whether
approved or experimental, is restoring the balance between
substrate influx and degradation in the key cells and tissues.2
In a large proportion of cases, the lysosomal enzymes at the
origin of these diseases are soluble acidic glycosidases produced
in the endoplasmic reticulum (ER), quality checked, and trans-
ported to the lysosome via the Golgi apparatus.3,4 The origin of
protein dysfunction causing LSDs is diverse; however, abnormal
protein folding during biosynthesis in the ER is often observed.
Enzyme replacement therapy (ERT),5 in which patients are
regularly supplemented with an exogenous recombinant enzyme,
and small-molecule substrate reduction therapy (SRT),6,7 relying
on the inhibition of substrate biosynthesis, represent the
primary treatment options that are approved for patients with
some LSDs. More recently, an alternative therapeutic paradigm
consisting of the elaboration of specific ligands that selectively
bind and stabilize otherwise unstable mutant enzymes to
increase total cellular levels and improve lysosomal trafficking
and activity, so-called pharmacological chaperones (PCs), has
emerged (Fig. 1).8,9
PCs are low molecular weight compounds that stabilize the
native conformation of a mutant enzyme in the ER, allowing it
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to escape aggregation and premature degradation by the
ER-associated degradation pathway. The properly folded mutant
enzyme, stabilized by the PC, can then be transported to the
Golgi apparatus for maturation and reach the lysosome, increas-
ing the residual enzyme activity of the cells. Although it might
appear contradictory, most PCs have also been competitive
inhibitors of their target enzyme.10 Once the PC:enzyme complex
reaches the lysosome, the large amounts of stored substrates
are believed to displace the PC and take over the stabilization
of the mutant enzyme. Contrary to ERT and SRT, PC therapy
addresses not only substrate accumulation but also the protein
folding defects and their potential contributions to the patho-
physiology of the disease.11 Moreover, PCs can in principle be
subjected to medicinal chemistry optimization strategies to
improve pharmacokinetics, toxicity and biodistribution properties,
particularly in view of reaching the central nervous system.12 This
is of special relevance to LSDs, since most of these conditions
imply neurological symptoms that cannot be addressed by ERT
strategies.13
Some molecules with therapeutic promise as PCs have been
identified by high throughput screening of libraries in view
of drug repositioning.14 In such cases there is no apparent
resemblance between the structure of the chaperone and the
substrate, which in the case of a lysosomal glycosidase is an
oligosaccharide or a glycoconjugate. Lately, macromolecular
chaperone candidates consisting of multiple copies of a sugar-
like motif displayed at the surface of a polyantennaeted scaﬀold
have also been proposed.15,16 The focus of this Feature Article,
however, is glycomimetic-based active site-directed pharmaco-
logical chaperones: small molecules that emulate the structure of
the monosaccharide unit cleaved oﬀ by the target LSD-associated
glycosidase, eventually incorporating additional non-glycone
Fig. 1 Schematic representation of the therapeutic strategies available for
LSDs: ERT, enzyme replacement therapy; SRT, substrate reduction therapy;
and PC, pharmacological chaperone.
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moieties intended to improve mutant enzyme binding, folding
and rescuing capabilities.17 Glycomimetics can be designed to
achieve all of the requirements for a potent therapeutic drug
and thereby create a new and innovative source of novel
therapeutics.18 Understanding the detailed molecular basis of
the interaction between the native or mutant enzyme and the
natural sugar substrate or their functional analogues is essential
for these channels. X-ray crystallography of the co-crystallized
glycomimetic ligand and the lysosomal glycosidase provide the
most reliable data for PC rational design.19 This knowledge is
complemented by the evolving understanding of the mecha-
nisms leading to loss of function of mutant forms that retain
catalytic activity or that have only modestly compromised func-
tion due to premature degradation or ER aggregation.20 To
illustrate the current developments in glycomimetic-based PC
design, we have selected relevant examples, preferentially from
contributions made in the last five years that involve either
in cellulo or in vivo evaluation, for three representative LSDs:
Gaucher disease (GD), GM1-gangliosidosis (GM1) and Fabry
disease (FD).
GD is an inherited metabolic disorder caused by mutations
in the glucocerebrosidase gene (GBA1) that results in defective
and insuﬃcient activity of the enzyme b-glucocerebrosidase
(EC 3.2.1.45; GCase), which catalyzes the hydrolysis of the
b-glycopyranosyl linkage in glucosylceramide (1; Fig. 2).21 For
operational purposes, GD can be subdivided into 3 types based
on the age at onset and neurological manifestations. Type 1 GD
was considered to have no discernible neuronopathic features.
The infantile-onset acute neuronopathic form, Type 2, carries a
very severe prognosis, whereas Type 3 GD is a chronic neuro-
nopathic form. Although GD is the most common LSD, it is
nevertheless relatively rare and classified as an orphan disease.
The prevalence of GD in the general population is estimated to
be 1 in 57 000 live births, but this increases to 1 in 1000 in
Ashkenazi Jews, with 5–10% of patients worldwide having the
neuronopathic forms. Whereas ERT and SRT are available for
Type 1 GD, to date, there are no approved treatments for the
neurological manifestations of Type 2 and 3 GD.22 Recent
findings have also drawn attention to impaired cognition, albeit
subtle, in Type 1 GD patients, a manifestation that is not addressed
by ERT or SRT. The frequency of GD and Lewy-body dementia is
also greatly increased in the healthy parents and other hetero-
zygous GD carriers. Additionally, mutations in the GBA1 gene
confer the greatest risk of Parkinsonism in all populations.23
Mutations in the GLB1 gene encoding for the precursor form
of human lysosomal b-galactosidase (EC 3.2.1.23; b-Gal) are at
the origin of GM1, an autosomal, recessive, severe neuro-
degenerative disorder that has been classified into three clinical
phenotypes, infantile, juvenile, and adult forms, depending
on the onset and severity.24 b-Gal catalyzes the hydrolysis of
terminal b-galactopyranosyl residues from various substrates,
including ganglioside GM1 (2; Fig. 2). The estimated incidence
of GM1 is 1 : 100 000–200 000 live births, with no effective
medical treatment available; the inability of proteins to cross
the blood–brain barrier makes ERT inefficient when the central
nervous system is involved.25
FD is an X-linked LSD caused by mutations in the GLA gene
that encodes lysosomal a-galactosidase A (EC 3.2.1.22; a-Gal A).
a-Gal A cleaves a-linked galactopyranosyl moieties of neutral
glycosphingolipids, mainly globotriaosylceramide (3, GL-3;
Fig. 2). Deficiency in a-Gal A activity results in the accumulation
of GL-3, which gives rise to a variety of clinical manifestations
such as cardiomyopathy, renal dysfunction, stroke, and, in some
cases, neurological symptoms. Although FD follows X-linked inheri-
tance, heterozygous females can be symptomatic. The incidence of
FD, according to the literature, varies from 1 :40000 to 1 :170000
live births. While ERT is available, its impact on the life quality of
patients is not always satisfactory.26 Indeed, ERT in advanced FD
seems to be of doubtful benefit and improved treatment options
are needed.27
While all these three diseases originate from the arrest of
glycosphingolipid metabolism, the critical biochemical step at
which it blocks is diﬀerent for each condition. Reactivation of
substrate hydrolysis with pharmacological chaperones implies
rescuing the precise dysfunctional glycosidase without inter-
fering with any other enzymatic process. Selectivity is going
to be, thus, a critical aspect for clinical prospects that must be
considered in any glycomimetic chaperone design. It entails
endowing the candidates with configurational (e.g., between
enzymes acting on gluco or galacto substrates) and anomeric
(e.g., between enzymes acting on b- or a-galactopyranosyl sub-
strates) discrimination capabilities. Mimicking the configura-
tional pattern of the glycone part of the putative substrate with
iminosugars, monosaccharide analogues in which the endo-
cyclic oxygen is replaced by an amine nitrogen, has been by far
Fig. 2 Structures of the substrates accumulated in the lysosomes of
patients suﬀering from Gaucher disease (1), GM1 gangliosidosis (2) and
Fabry disease (3). The monosaccharide unit cleaved oﬀ by the corres-
ponding disease-associated lysosomal glycosidase is colored in red, blue
and green, respectively.
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the most thoroughly investigated approach. Indeed, iminosugars
had already met considerable success in the discovery and
elaboration of competitive glycosidase inhibitors.28–30 Tuning
chaperoning properties turned to be a more complex task, how-
ever, requiring higher doses of creativity eventually leading to new
PC prototypes. Efforts towards new PC therapies for Gaucher
disease, the LSD that has preferentially attracted the chemists’
attention, better illustrate this point. For the sake of clarity, we
have chosen to subdivide the discussion of this section by
compound families rather than following a chronological scheme.
The sections regarding GM1 and FD serve to highlight the
importance of moulding glycomimetic structure to impart selec-
tivity towards enzymes differing on the anomeric configuration of
the hydrolysed glycosidic bond. Opportunities for further improv-
ing chaperone function by chemical tailoring will be presented in
the Concluding remarks and future outlook section.
Glycomimetic-based PCs for Gaucher
disease
Unmodified iminosugars
The focus for pharmacological chaperone candidates was initially
placed at unmodified iminosugars behaving as competitive
inhibitors of the target lysosomal enzyme, i.e. b-glucocerebrosidase
in the case of Gaucher disease. Among those, isofagomine (IFG, 4) is
the compound that reached a more advanced stage in view of
drug development (planned trademark Pliceras). IFG exhibited
promising results ex vivo and in vivo as a GCase enhancer,31
with several mutant GCases associated with GD showing
increases in enzymatic activity and protein in response to the
chaperone. Deceivingly, IFG failed to proceed to Phase II
clinical trials (Phase III in combined therapy with recombinant
GCase) after scarce improvement in key GDmarkers.32,33 In vivo
studies with a mouse model for neuronopathic Gaucher disease
showed that IFG significantly attenuated the progression of the
disease by increasing GCase levels and mediating the suppres-
sion of proinflammation, but this was not correlated with a
reduction in the accumulation of lipid substrates.34,35 One
caveat is that IFG is an inhibitor of GCase in the lysosome.
Although this inhibitory eﬀect is reversible, a net gain in
enzyme activity is only achieved after the removal of the drug
from the medium, meaning that medical use would probably
require a very delicate intermittent dosing of the iminosugar.
It is also of note that it requires a three orders of magnitude
higher concentrations of IFG to increase GCase activity in cells
(10–100 mM) compared with the amount needed to inhibit
GCase in the in vitro assays (5–100 nM).36 The most likely
explanation for this difference is that IFG, a highly hydrophilic
molecule, is transported into the ER and the lysosome very
inefficiently; similar unfavourable membrane-crossing pro-
perties may apply for other canonic iminosugars evaluated as
pharmacological chaperones for GD such as calystegines
A3 (5), B1 (6), B2 (7) and C1 (8), 1,5-dideoxy-1,5-iminoxylitol
(DIX, 9),37,38 noeurostegine39 (10) or the 3,4,5,6-tetrahydroxy-
azepane 11 (Fig. 3).40
N-Alkylated iminosugars
The discovery that iminosugars with N-linked alkyl chains of
varying lengths, e.g. N-butyl and N-nonyl DNJ (NB-DNJ and
NN-DNJ; 12 and 13, respectively; Fig. 4), can bind to GCase
and stabilize substrate bound conformations of mutant GCase
forms had a considerable impact in the field by providing an
appealing strategy to improve the metabolic properties of
chaperone aspirants (cell and ER permeability, for example).
The alkyl chains of NB-DNJ and NN-DNJ are oriented towards the
entrance of the active site in the corresponding chaperone:GCase
complexes, participating in favourable hydrophobic contacts
with amino acid residues, contributing to the complex stability
and ensuring the correct initial folding and traﬃcking of mutant
GCase to the lysosome.41 For the particular case of the N370S
mutation, the most prevalent in Type 1 GD patients, structural
and biochemical data indicated that the protein is already
correctly folded and that the mechanism by which competitive
inhibitors increase the lysosomal levels of GCase is by reducing
degradation by proteases within the lysosome rather than by
having an eﬀect on protein folding and traﬃcking.42 NB-DNJ,
and possibly other chaperones, also mediates the formation of
the enzyme–substrate complex in the lysosome and the inter-
action of GCase with saponin C,43 an established activator for
the hydrolysis of glucosylceramide by GCase in lysosomes that is
compromised in the N370S mutant.44
Following the pioneering work on NB-DNJ and NN-DNJ,
several examples of N-alkylated iminosugar frameworks have
Fig. 3 Structures of some unmodified iminosugars behaving as GCase
inhibitors and chaperones.
Fig. 4 Structures of some N-alkylated iminosugars evaluated as PCs for GD.
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been proposed as pharmacological chaperones for GD. The
common concept is to conjugate an iminosugar with a lipo-
philic moiety; the former may mimic the sugar part or the
transition state towards glycosidic cleavage and the latter may
mimic the ceramide aglycone of the natural substrate, gluco-
sylceramide (1, Fig. 2). To accelerate chaperone discovery,
molecular diversity strategies have been implemented. Thus,
in 2011 Gouin et al.45 developed an eﬃcient ‘‘click’’ procedure
to tether hydrophobic substituents to DNJ through the popular
copper catalyzed azide–alkyne cycloaddition (CuAAC) reaction.46
Cycloadduct 14, bearing a phenoxymethylene group at position
C-4 of the triazol ring (Fig. 4), was identified as the most
promising compound from a set of fourteen amphiphilic DNJ
derivatives, increasing mutant GCase activity in N370S/N370S
Gaucher cells nearly 2-fold at 20 mM compared to untreated cells.
In the same optics, Cheng et al.47 used N-(4-aminobutyl) deriva-
tives of DNJ, 2,5-dideoxy-2,5-imino-D-arabinitol (DAB) and
2,5-dideoxy-2,5-imino-D-mannitol (DMDP) as scaffolds to generate
a large library of glycomimetics by amidation of the terminal
primary amine group in the appendage. The authors identified
potent GCase inhibitors in the three series, but whereas DNJ
candidates (15) did also inhibit lysosomal a-glucosidase, the
pyrrolidine counterparts were selective for the target enzyme, with
compounds 16 and 17 (Fig. 4) promoting 2.5- and 2.2-fold activity
enhancements in homozygous N370S human fibroblasts at 6.2
and 1.5 mM concentrations, respectively.
Butters, Ye and coworkers proposed a diﬀerent prototype for
GD chaperones based onN-substituted d-lactams with a carbonyl
group instead of the hydroxymethyl group in a deoxynojirimycin
(DNJ) scaﬀold.48 The sp2-hybridized carbon was designed to
distort the ring to a half-chair conformation, which according
to docking experiments was expected to lead the protruding
carbonyl group to interact with the surrounding amino acids and
stabilize the substrate-bound conformation of GCase. Indeed,
several of the synthesized N-alkylated derivatives with a con-
figurational pattern matching that of DNJ (D-gluco) elicited
significant enzyme activity enhancements in Gaucher lympho-
blasts (N370S), with the N-octyl and N-(6-hydroxyhexyl) deriva-
tives 18 and 19 (50 mM concentration; Fig. 5) reaching
outstanding 6.2- and 4.1-fold relative to untreated control cells,
respectively. It is worth noting that d-lactams related to the
galacto-type epimer of DNJ (D-galacto configuration) also showed
GCase chaperoning activity in the same GD cells (e.g. 2.9-fold for
the N-decyl derivative 20 at 50 mM). Further work by the same
group showed that the homologous e-glucono- and e-galactono-
lactams (e.g. the N-nonyl derivatives 21 and 22, respectively;
Fig. 5) did also increase GCase activity in N370/N370 GD
lymphoblasts up to 2.4 fold at 50 mM concentration, meaning
a better performance as compared with NB-DNJ and NN-DNJ in
spite of their neutral character.49
C-Alkylated iminosugars
Isofagomine-type iminosugar glycomimetics (1-azasugars), which
comprise IFG, the calystegines and DIX (Fig. 3), bind to GCase
with the nitrogen atom occupying a portion analogous to the
anomeric carbon of glucose in GCase-bound glucosylceramide
(C-1), whereas deoxynojirimycin-type iminosugars do so in a
mode in which the nitrogen atom matches the endocyclic oxygen
(O-5). The ensemble of data on N-alkylated iminosugars as GD
pharmacological chaperones support that in the second binding
mode accommodation of the N-substituent in the hydrophobic
pocket of GCase is very favourable, to the point that it imparts
GCase inhibition properties even when the parent iminosugar
may not be an inhibitor of the enzyme. In stark contrast,
N-alkylation of iminosugar behaving as 1-azasugars, for instance
the N-octyl derivative 23 (Fig. 6), is either detrimental or has little
eﬀect on GCase binding aﬃnity.50 Interestingly, moving the
alkyl substituent from the N-atom to the adjacent C-atom in
1-azasugars restores the glycomimetic:GCase fitting capabilities,
leading to strong GCase inhibitors51 with GCase chaperoning
properties, such as the C-6-propyl IFG derivative 24 (1.5-fold GCase
activity enhancement in N370S GD fibroblasts).52 The potential of
this strategy to develop new GD chaperones was elegantly demon-
strated by Compain, Martin and Asano, who developed a-1-C-
nonyl-DIX (25; Fig. 6) as one of the most potent mutant GCase
enhancers ever reported: 1.8-fold activity increase in N370S fibro-
blasts at a concentration as low as 10 nM.53
Withers and coworkers took advantage of the thiol–ene
click-type reaction54 to rapidly generate a collection of sixteen
1-C-alkylated DIX derivatives bearing various lipophilic sub-
stituents (general structure 27) from the unsaturated DIX pre-
cursor 26 and different thiols (Fig. 7, upper lines).55 Library
members 28 and 29 exhibited the highest mutant GCase activity
enhancement capabilities among the prepared compounds,
reaching 3.4- and 1.4-fold in homozygous Gaucher N370S and
L444P fibroblasts, respectively, when used at 100 mMconcentration.
Fig. 5 Structures of N-alkylated iminosugar lactams behaving as GD PCs. Fig. 6 Structure of the N- and C-alkylated 1-azasugar derivatives 23–25.
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The latter result is particularly notable, given that the L444P
mutation, with a high prevalence in Type 3 Gaucher patients,56
is not located in the GCase domain harbouring the catalytic
site57 and is refractory to most pharmacological chaperone
candidates (Fig. 8).
More recently, Compain, Delgado and coworkers expanded
the battery of 1-C-alkylated DIX derivatives by using the
alkynyl DIX precursor 30 and applying CuAAC ligation chem-
istry, thereby accessing 1,2,3-triazole adducts 31 (Fig. 7, lower
lines).58 The 3-(trimethylsilyl)propyl derivative 32, exhibited the
best activity enhancement within the prepared compounds,
reaching up to 4-fold in Gaucher fibroblasts containing the
G202R mutation in homo or heterozygosis, associated with the
neuronopathic phenotype of the disease (Fig. 8), at 100 nM
concentration.
Amphiphilic pyrrolidine-type iminosugars can probably
adapt to either of the two above commented glycomimetic
orientations, namely with the nitrogen atom in a location
equivalent to C-1 or O-5 in glucopyranosides, upon binding to
GCase, depending on whether the lipophilic substituent is
attached to the nitrogen atom (e.g. 16 and 17) or to an adjacent
carbon atom. For instance, the a-1-C-tridecyl-DAB derivative 33
(Fig. 9) reported by Kato and coworkers59 behaved as a strong,
selective and competitive inhibitor of GCase (Ki 0.71 mM) and
was able to enhance the activity of the mutant enzyme in
N370S/N370S Gaucher fibroblasts by 1.5-fold at 1 mM concen-
tration, meaning a ten times lower optimal concentration as
compared with isofagomine (4, Fig. 3). A docking study of 33
to human GCase supported the 1-azasugar binding mode,
benefitting from a hydrogen bonding network involving the
protonated imino group and the triol system analogous to that
encountered for IFG and from favourable hydrophobic contacts
between the tridecyl chain and the amino acids coating the
hydrophobic pocket at the entrance of the catalytic site.
sp2-Iminosugars
The chemical reactivity and conformational properties of classical
iminosugars is overwhelmingly dominated by the amine character
of the sp3-hybridized nitrogen atom in the azaheterocyclic
skeleton. Most importantly, the intrinsic instability of aminal
Fig. 7 Thiol–ene (upper lines) and CuAAC (lower lines) strategies for the
generation of C-alkylated DIX derivatives as PCs for GD.
Fig. 8 X-ray structure of acid-b-glucosidase (reproduced with permission
from ref. 57;r2003 European Molecular Biology Organization). Domain I is
shown in magenta, domain II in green and domain III, which is the catalytic
domain, in blue. The active-site residues E235 and E340 are shown as ball-
and-stick models. Some representative GD-associated GCasemutations are
shown as balls, with those that cause predisposition to severe (types 2 and 3)
and mild (type 1) disease in red and yellow, respectively. The most common
GCase mutations in non-neuronopathic (N370S) and neuronopathic (L444P)
forms of GD are shown in boxes.
Fig. 9 Structure of a-1-C-tridecyl-DAB (33) and its binding in the active
site of GCase as obtained by docking.
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functionalities makes iminosugars unsuitable to emulate the
acetal group of glycosides, the natural substrates of glycosidases.
Analogues of N- and S-glycosides, incorporating gem-diamine or
aminothioacetal pseudoanomeric centers, are likewise labile, which
in practice restrict the possibility to incorporate pseudoaglycon-like
moieties with a precise orientation to the synthetically more
demanding iminosugar-C-glycoside representatives.60 The
failure at properly mimicking the anomeric linkage is probably
at the origin of the low selectivity frequently encountered for
iminosugars towards enzymes acting on anomeric substrates
as well as among isoenzymes, which seriously hampers their
progress into the clinics. Moreover, owing to their basic char-
acter iminosugars are largely protonated at physiological pH,
which further restrains the possibility to convey significant
binding aﬃnity diﬀerences towards the target glycosidase at
neutral (ER) and acidic environments (lysosome), a critical aspect
for chaperone candidates.
Replacement of the underlining amine group of iminosugars
into a trigonal planar pseudoamide-type nitrogen (N-carbonyl,
N-thiocarbonyl, N-imino group), with substantial sp2-hybridation
nature, drastically modifies the chemical and stereoelectronic
properties of iminosugar frameworks, oﬀering broad opportu-
nities for pKa tuning compatible with the incorporation of
virtually any type of exocyclic substituent. Members of this
family of glycomimetics, generically termed sp2-iminosugars,
such as the natural alkaloid kifunensine (34) or the synthetic
glycoamidines (e.g. 35), glycohydroxymolactams (e.g. 36), glyco-
imidazoles (e.g. 37) and glycotetrazoles (e.g. 38), have been
known for a long time (Fig. 10),61 but the expansion of sp2-
iminosugars as glycosidase activity modulators started only in
the late 90’s with the initial report on the inhibitory properties
of hemiaminal-type representatives (Fig. 11).62 The p orbital
locating the lone pair of the endocyclic N-atom in pseudoamide
functionalities, with p-symmetry, very eﬃciently overlaps with
the s*-antibonding orbital of an axially-oriented contiguous
pseudoanomeric bond, drastically enhancing the hyperconju-
gative contribution to the generalized anomeric eﬀect, enabling
access to unique glycomimetics with stable N–C1–X (X = O, N, S
or C) pseudoanomeric centers.63
The chemical synthesis of reducing sp2-iminosugars is
significantly simplified as compared to classical iminosugars
and takes advantage of the chemoselective intramolecular
nucleophilic addition of pseudoamide nitrogens (carbamate,64
thiocarbamate,65 urea,66 thiourea,67 isourea,68 isothiourea,69
guanidine,70 sulfamide,71 and thiohydantoine72) to the masked
aldehyde group of a carbohydrate template in the open chain
form (Fig. 11). The substitution pattern, configurational profile
and ring size of the final compounds can be varied in a
predictable manner by tailoring the monosaccharide precursor,
making the procedure very well-suited for diversity-oriented
strategies. Such favorable features have been exploited to opti-
mize the chaperoning capabilities towards several LSD-associated
glycosidases.
Amphiphilic bicyclic sp2-iminosugars related to the natural
reducing alkaloid nojirimycin (NJ), such as 5N,6O-(N0-octyl-
iminomethylidene)nojirimycin (39, NOI-NJ) or its 6-thio (40,
6S-NOI-NJ) and 6-amino-6-deoxy (41, 6N-NOI-NJ) analogues
(Fig. 12A), are anomeric-specific inhibitors of b-glucosidases,
including the lysosomal acid b-glucosidase (GCase) associated
with Gaucher disease (IC50 values 1.3–14.4 mM).
73 X-ray structural
evidence demonstrated that the axial orientation of the pseudo-
anomeric OH group in the ground state of the glycomimetics in
aqueous solution switch to equatorial (b-configuration) when
complexed with the enzyme, with the octyl chain locating at the
hydrophobic pocket at the entrance of the catalytic site (Fig. 12B
and C).74 Interestingly, all three compounds behaved as about
one-order-of-magnitude stronger inhibitors of GCase at neutral
(pH 7) than at acidic pH (pH 5.2) in human normal as well as
Gaucher fibroblasts. The chaperoning capabilities were assessed
by determining the enzyme activity enhancements in GD cells
from patients with seven different GCase mutations, namely
F213I/F213I, G202R/L444P, N188S/G193W, N370S/N370S, F213/
L444P, L444P/RecNcil and L444P/L444P, in comparison with
NN-DNJ (13, Fig. 4). All the sp2-iminosugars proved largely super-
ior to NN-DNJ in the F213I, G202R and N188S variants, associated
with orphan neuronopathic forms of the disease, with GCase
activity enhancements ranging from 2 to 3-fold at 30 mM. In cellulo
ten-day’s time course experiments showed that a maximum activity
enhancement is achieved at day 3–4, then reaching a plateau with
no affectation of cell viabilities. When cells were deprived of the
chemical chaperones on day 4, the activity gradually decreased to
the basal level within one to three days (Fig. 12D). The hypothesized
endogenous GCase rescuing and trafficking restoring mechanism
was confirmed by colocalization experiments using a fluorescently
labeled sp2-iminosugar chaperone in combination with immuno-
detection of GCase, calnexin (ER) and the lysosomal-associated
membrane protein-2 (LAMP-2).75
Fig. 10 Structure of some natural and synthetic non-reducing sp2-
iminosugars.
Fig. 11 General structure and retrosynthetic scheme for reducing sp2-
iminosugars (D-gluco series); the p and s* orbitals involved in hyper-
conjugative contribution to the anomeric eﬀect are depicted.
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Most in vitro studies focusing on the basic mechanism and
small compound screening eﬀorts for LSD therapies have been
performed on patient fibroblasts, a cell type not primarily
aﬀected in patients. In 2013, Tiscornia et al.76 described the
development of an induced pluripotent stem cell (iPSc) model
for the acute neuronopathic form of GD (early onset GD Type 2)
that showed the same GCase mutations (G202R/L444P) and low
GCase activity as the original fibroblasts they were derived
from. They subsequently diﬀerentiated the iPSc into dopaminergic
neurons and used them as a platform to test the chaperone
capabilities of a focused library of reducing sp2-iminosugars
related to nojirimycin and galactonojirimycin. Two compounds,
namely the isourea-type derivative NOI-NJ and the isothiourea
analogue 5N,6S-N0-[4-(adamantane-1-caboxamido)butylimino-
methylidene]-6-thionojirimycin (6S-AdBI-NJ),77 were found to
increase GCase levels and activity in the diﬀerentiated neuronal
cultures over 3-fold at a relatively low concentration (30 mM;
Fig. 13A). Notably, 6S-AdBI-NJ is very well adept at forming
inclusion complexes with b-cyclodextrin (bCD) derivatives,
which was further exploited to elaborate chaperone delivery
systems targeting macrophages, the most aﬀected cells in GD
patients, such as the trimannosylated bCD conjugate Man3-bCD
(Fig. 13B).78 Given estimates that only small increases in GCase
activity would be required to achieve a clinical eﬀect, these
results support further development of these compounds as
chaperone candidates for Type 2 neuronopathic GD, which
currently lacks therapeutic options and is lethal.
sp2-Iminosugars having a fused bicyclic skeleton system-
atically failed to promote significant activity GCase enhance-
ments in cells with the L444P/L444P genotype, one of the most
prevalent GD-causing mutations in humans that is associated
with the late onset neuronopathic variant (GD Type 3). A survey
of crystal structures of chaperone:GCase complexes evidenced
that the enzyme has a propensity to induce a conformational
change in the azaheterocycle ring of classical79 as well as
sp2-iminosugars,74 from chair to envelop or skew-boat, to optimize
fitting. This feature seems to restrain the correct folding
stabilization and traﬃcking restoration capabilities of the
chaperones to those cases where the point mutation is located
in the catalytic domain of GCase. Interestingly, undistortable
sp2-iminosugars related to the calystegine iminosugar family,80
such as the N-[(4-adamantanecarboxamido)butylthiocarbamoyl]-
1,6-anhydro-L-idonojirimycin derivative 43 (NAdBT-AIJ; Fig. 14A),
Fig. 12 (A) Structures of 5N,6O-(N0-octyliminomethylidene)nojirimycin
(39, NOI-NJ), its 6-thio (40, 6S-NOI-NJ) and 6-amino-6-deoxy (41,
6N-NOI-NJ) analogues in water solution; note the a-configuration of
the pseudoanomeric center and the axial disposition of the corresponding
hydroxyl. (B) Crystal structure of the complex between 6S-NOI-NJ and
recombinant human GCase; the anomeric hydroxyl is indicated with a red
arrow. (C) Representation of GCase-bound 6S-NOI-NJ showing the
b-oriented anomeric OH group. (D) Chaperone activity of 6N-NOI-NJ in
homozygous F213I Gaucher fibroblasts (10-days time course; filled circles);
a subset of cells was cultured with chaperones for four days, washed and
further cultured without the drug for six days (empty circles).
Fig. 13 (A) Structures of the sp2-iminosugar chaperones NOI-NJ (39) and
6S-AdBI-NJ (42) and GCase activity enhancements in G202R/L444P
dopaminergic neurons diﬀerentiated from induced pluripotent stem cells
treated with 30 mM concentrations of the chaperones. (B) Structure of
the cyclodextrin conjugate Man3-bCD devised for macrophage-selective
delivery of 6S-AdBI-NJ.
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were found to be eﬀective at propagating the GCase refolding
eﬀect in stable transfected COS-7 cells expressing L444P GCase
as well as in fibroblasts of GD patients homozygous for this
mutation, facilitating translocation of the enzyme from the ER
to the lysosome and leading to above 3-fold GCase activity
enhancements.81
The oxa-nor-tropane skeleton in NAdBT-AIJ was built from
a 5-deoxy-5-thioureido-L-idonofuranose precursor following
acid-catalyzed deprotection. Sequential furanose- piperidine
rearrangement and intramolecular glycosidation involving
OH-6 occurred spontaneously,82 aﬀording the calystegine-type
chaperone in high yield (Fig. 14A). The eﬃciency of NAdBT-AIJ
in improving the L444P/L444P GD condition in fibroblasts was
further confirmed by Sa´nchez-Alcazar and coworkers.83 These
authors demonstrated that, in addition to the lysosome, the
mitochondria function is severely aﬀected in GD patients, leading
to membrane depolarization, reduced ATP levels, increase in
reactive oxygen species (ROS) production, mitophagy activation
and impaired autophagic flux. Based on these findings, they
conceived a combined therapy targeting both organelles by
co-administration of the NAdBT-AIJ chaperone and coenzyme
Q10 (CoQ), an antioxidant and mitochondrial energizer that is
currently considered as a potential experimental drug for the
treatment of neurodegenerative diseases in general84 and lyso-
somal diseases in particular.85 Significant synergistic eﬀects
were observed, which in addition to the accessibility of both
active agents makes the strategy very promising for the treat-
ment of neuronopathic forms of GD that are not responsive to
ERT (Fig. 14B).
Aminocyclitols
Most research eﬀorts towards the design of glycomimetic-type
pharmacological chaperones have taken advantage of the oppor-
tunities that incorporation of nitrogen functionalities in poly-
hydroxylated scaﬀolds oﬀers for pH-dependent (therefore cell
organelle-dependent) modulation of the aﬃnity and selectivity
towards the target enzyme and improvement of the pharmaco-
kinetic properties. Nitrogen-in-the-ring monosaccharide mimics
have been generally privileged, but alternative prototypes with the
key nitrogen functionality at an exocyclic location, such as the
sugar-like aminocyclitols, have also shown considerable promise.
Thus, in 2004 Lin et al. reported on the GCase chaperoning
capabilities of N-octyl-b-valienamine (NOV, 44; Fig. 15) in GD
fibroblasts harbouring the F213I/F213I mutation.86 A computa-
tional study supported that NOV (predicted pKa = 8.69) is
protonated in the whole pH 5–7 window.87 At pH 7 (ER), the
aspartic acid residue Asp127 of GCase is deprotonated and
tolerates a deeper binding of the chaperone, allowing an
efficient interaction between the amino group of NOV and the
catalytic acid Glu235. Protonation of Asp127 at pH 5 (lysosome)
weakens the interaction and promotes dissociation of NOV
from the enzyme, allowing substrate processing (Fig. 15). The
location of the N-atom is thus critical for the NOV mechanism
of action and possibly for other aminocyclitols.
Casas and coworkers and Llebaria and co-workers have
conducted an intense research on the synthesis and evaluation
of aminocyclitol-type chaperones, with several candidates for
GD on record. In 2009 it was found that amino-scyllo-inositol
derivative 45 (Fig. 16), bearing an N-decyl substituent, behaved
as a pharmacological chaperone in GD patient fibroblasts bearing
Fig. 14 (A) Structure and retrosynthetic scheme for the rigid sp2-iminosugar
chaperone NAdBT-AIJ. (B) GCase activity enhancements in normal (control)
and L444P/L444P GD fibroblasts promoted by coenzyme Q10 (CoQ, 25 mM),
NAdBT-AIJ (25 mM) and the combined treatment with CoQ + NAdBT-AIJ
(25 mM + 25 mM).
Fig. 15 Schematic representation of the interactions of NOV with Asp127
and Glu235 at the active site of GCase at pH 7 (Asp127 deprotonated) or
pH 5 (Asp127 protonated) as obtained by computational calculations.
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the neuronopathic L444P/G202R and L444P;E326K/G202R
genotypes.88 Two years later bicyclic isoureas and guanidines
with cis ring fusion (e.g. amino-myo-inositol derivatives 46
and 47) were developed as extremely potent inhibitors of
recombinant GCase (Ki values in the range 2–10 nM).
89 The
most efficient compound in this work, namely 46, promoted a
2.1-fold GCase activity enhancement in N370S/N370S Gaucher
lymphoblasts when used at 100 nM concentration. Remarkably,
GCase activity in L444P/L444P lymphoblasts was also increased
by up to 50% at 10 nM. Further improvement was achieved by
preparing diantennaeted cyclitols bearing two vicinal alkylamino
groups (e.g. 48)90 or, even better, aminocyclitols with adjacent
N- and O-alkyl substituents: compound 49 (Fig. 16), incorporat-
ing two nonyl chains, produced maximum increases of GCase
activities of 90% in N370S lymphoblasts at 1 nM and 40% in
L444P lymphoblasts at 0.01 nM.91
The data collection on aminocyclitols reveals the utmost
importance of the configurational pattern and the nature of the
exocyclic substituent in their inhibitory/chaperoning capabi-
lities towards GCase. Amino-myo-inositols provided the best
results in the bicyclic series, whereas both monocyclic scyllo-
andmyo-inositol derivatives showed promise as pharmacological
chaperones for GD. Amphiphilicity is also a general requisite.
In this sense, the incorporation of adamantanyl substituents,
already found beneficial in iminosugar and sp2-iminosugar
frameworks, represented an interesting option. Thus, com-
pounds 50 (scyllo) and 51 (myo) induced outstanding 120%
and 150% GCase activity increases, respectively, in homozygous
L444P fibroblasts when used at 50 and 100 mM concentra-
tions.92 Alternatively, the CuAAC click-type reaction can be used
to generate molecular diversity at the N-alkyl moiety. The
resulting 1,2,3-triazol adducts, e.g. amino-scyllo-inositols 52
and 53 (Fig. 16), were particularly eﬃcient as chaperones in
G202R/G202R GD fibroblasts, reaching up to 90% mutant
GCase activity enhancements.93
Aminosugars
The observation that the presence of a nitrogen atom in the
glycone moiety of glycomimetics is not a sine qua non pre-
requisite for strong GCase binding led Castillo´n, Ortiz Mellet
and coworkers to propose the pyranose ring typical of mono-
saccharides as a scaﬀold for chaperone design.94 In principle,
this approach should warrant glycone-driven specificity towards
the target glycosidase while greatly simplifying the synthetic
scheme. As a proof of concept, these authors developed deriva-
tives with the cis-1,2-fused (gluco)pyranose-2-alkylsulfanyl-1,3-
oxazoline (PSO) structure (54; Fig. 17) as conformationally locked
N-glycoside analogues and demonstrated that their GCase
inhibitory activity was drastically dependent on the nature of
the exocyclic S-substituent. Installation of a hexadecyl chain
with either a terminal hydroxy (PSO-HHD; 55) or a fluoro group
(PSO-FHD; 56) provided the stronger GCase inhibitors within
the series (IC50 values 12 and 3.9 mM, respectively), suggesting
that PSO:GCase complexes might be stabilized by a long-range
hydrogen bonding interaction involving this terminal group
and an amino acid residue located at a maximum distance of
22 Å from the catalytic site (Fig. 17).95 PSO-HHD and PSO-FHD
were able to enhance mutant GCase activity in N370S/N370S GD
fibroblasts by 55% and 62% at 30 and 60 mM concentrations,
respectively, doubling the maximum GCase activity enhance-
ment of the non-glycomimetic chaperone Ambroxols, currently
in pilot trials in humans,96 in a parallel assay (33 mM at 10 mM).
Following the same concept, Peregrina and coworkers97
proposed the aminopyrano[3,2-b]pyrrole (APP) framework 57
(Fig. 18) to build conformationally locked aminosugar C-glycosides
onto which two diﬀerent non-glycone substituents can be
incorporated to optimize interactions with GCase. APP deriva-
tives bearing one (O- or N-) or two palmitoyl chains behave
Fig. 16 Structures of aminocyclitol derivatives developed as pharma-
cological chaperones for GD-associated mutant GCase variants.
Fig. 17 General structure of the PSO framework (54) and of the S-(o-
hydroxyhexadecyl) and S-(o-fluorohexadecyl) derivatives 55 (PSO-HHD)
and 56 (PSO-FHD), respectively (up), and 3D molecular model of PSO-
HDD (carbons in grey, oxygens in red, nitrogen in light blue, sulfur in
yellow; hydrogens have been omitted for the sake of clarity) with indica-
tion of the distance between the anomeric nitrogen atom and the terminal
substituent in the chain (down).
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as mM inhibitors of the enzyme, exhibiting one-order-of-magnitude
decrease in the inhibition potency on going from pH 7 to pH 5,
a favourable characteristic for pharmacological chaperone
candidates. The N-palmitoyl derivative 58 was the most eﬃcient
APP within the series, promoting relative GCase activity increases
of 1.3- and 1.5-fold in homozygous N370S and F213I GD fibro-
blasts, respectively, with no sign of toxicity. MD simulations of 58
in complex with the human enzyme supports the existence of a
hydrogen bond involving the amide proton and the carboxylate
group of the catalytic residue Glu235 that orients the palmitoyl
chain towards a hydrophobic pocket in the enzyme (Fig. 18).
Glycomimetic-based PCs for
GM1-gangliosidosis
The potential of the galacto-configured iminosugar 1-deoxy-
galactonojirimycin (DGJ, 59) and its N-butyl derivative (NB-DGJ,
60; Fig. 19) as pharmacological chaperones for b-galactosidase
mutants associated with GM1 was already explored by Suzuki
and coworkers in 2001.98 Significant enzyme activity increases
(2.1- to 6.1-fold) were observed in mouse fibroblasts expressing
human GM1 b-Gal variants corresponding to the juvenile
(R201C) or adult phenotypes (I51T, R201H or R457Q). The
increase was detected also in human fibroblasts from patients
with GM1-gangliosidosis with the I51T and R201C mutations
(3- and 7-fold, respectively) after culture with 1 mM DGJ for 4 days.
The rather high dose of iminosugar needed to have a relevant b-Gal
activity enhancement, a limitation also encountered when using
the monosaccharide D-galactose as the chaperone,99 and the lack of
discrimination capabilities of DGJ between b- and a-galactosidases
raise some concerns about unwanted side eﬀects that jeopardize
the progress of this approach into the clinics, however.
Later on, Wroddning and coworkers investigated the eﬀect of
the nature of the N-alkyl substituent on the chaperoning proper-
ties of DGJ derivatives towards b-Gal mutants.100,101 This work led
the authors to identify methyl 6-{[N2-(dansyl)-N6-(1,5-dideoxy-D-
galactitol-1,5-diyl)-L-lysyl]amino} hexanoate (DLHex-DGJ, 61; Fig. 19)
as a potent inhibitor of human lysosomal b-Gal (Ki 0.6 mM)
significantly enhancing residual b-Gal activity (up to 18-fold) in
homozygous R201C (juvenile GM1) and heterozygous R201H/
R457X, R201H/H281Y and R201H/S149F fibroblasts (adult GM1).102
Although the maximum increase was achieved at a concentration
of 500 mM, similar to that found for DGJ, in all single experi-
ments the presence of DLHex-DGJ at 20 mM concentration was
suﬃcient to yield more than 10% of the normal control mean
activity, which was proposed as the critical level for normal
substrate turnover. The minimal concentration of chaperone
necessary to reach this threshold in homozygous R201C fibro-
blasts was further reduced to 5 mM for the fluorous derivative
62103,104 and to only 1 mM for the long-chain dansylated N-alkyl-
DGJ derivative 63.105 Mahuran and coworkers reported a similar
result for N-nonyl-DGJ (NN-DGJ, 64; Fig. 19).106 This amphiphilic
iminosugar is a better inhibitor of b-Gal at neutral (IC50 6 nM) as
compared to acidic pH (IC50 120 nM at pH 4.3) and produced a
robust activity fold enhancement at 1.2 mM concentration in
several GM1 fibroblasts derived from patients bearing the
p.R201H/IVS14-2A4G (juvenile) and p.R201H/p.W509C (adult)
mutations. The chaperoning capabilities of NN-DGJ iminosugar
were also demonstrated in cells from a GM1 feline model.
In 2014 Siriwardena et al. proposed 1,5-dideoxy-1,5-iminoribitol
(DIR) iminosugar C-glycosides with general structure 65 (R = alkyl,
hydroxyalkyl or aryl; X = OH or H) as new chaperone candidates
for GM1 (Fig. 19).107 The authors conceived a straightforward
synthesis from D-ribose compatible with molecular diversity-
oriented strategies and generated a small library of compounds
from which selected members were assayed as b-Gal activity
enhancers in fibroblasts from a patient with GM1-gangliosidosis
heterozygous for the mutation p.R201H/IVS14-2A4G. The
2-hydroxy-2-phenylethyl derivative 66 exhibited the better
chaperoning behavior within the series, eliciting enzyme activity
Fig. 18 General structure of the APP framework (57) and of the
N-palmitoyl derivative 58 (left); a representative frame obtained from MD
simulations showing the hydrogen bonds between the glycone unit of
compound 58 and amino acid residues in the human GCase binding site is
also shown (right).
Fig. 19 Structures of iminosugar-type PCs for GM1.
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increases over 6-fold when used at 394 mM concentration.
Although no structural data are presented, the analogy of the DIR
skeleton with the epimeric 1,5-dideoxy-1,5-iminoxilitol (DIX; Fig. 3)
iminosugar core previously developed for Gaucher disease chaper-
one design is apparent, suggesting that the C-glycoside derivatives
65 probably bind to b-Gal in the 1-azasugar mode, that is, with the
substituent at C-5 in a position equivalent to the N-substituent in
DGJ derivatives. Recent results by Martin and coworkers further
support this notion.108 These authors found that the galacto-
configured glycomimetic 4-epi-isofagomine (67), a strong inhibitor
of b-Gal (IC50 0.4 mM), was able to promote a 2.7-fold activity
enhancement in GM1 fibroblasts harboring the R201C mutation
when used at 10 mM concentration. Interestingly, the a-5-C-hexyl-
DIR derivative 68 (Fig. 19), which was a much weaker inhibitor of
the enzyme (IC50 100 mM), increased themutant b-Gal activity by 2.1-
fold at the same concentration in the same cell line, underlining the
critical role of substituents at the C-5 position in controlling the
activity of b-Gal chaperones in the 1-azasugar series.
The synthesis in 2003 of N-octyl-epi-valienamine (NOEV, 69;
Fig. 20) by Suzuki and coworkers and its characterization as a strong
inhibitor of lysosomal b-galactosidase (IC50 0.2 mM) with very good
chaperoning capabilities at low concentration (0.2 mM) represented
a hallmark in the field of pharmacological chaperone therapy.109
NOEV, administered orally in water solution (1 mM) to mice
expressing human R201C b-Gal ad libitum, produced an increase
of enzyme activity and a parallel decrease in GM1-ganglioside in
the cerebral cortex and brainstem. Accumulation of tropomyosin
receptor kinase (Trk) receptors,110 p62 (a protein that regulates the
formation of protein aggregates) and ubiquitinated proteins,111
which also contribute to GM1 pathogenesis, was also reduced after
NOEV treatment. Most interestingly, NOEV treatment starting at the
early stage of disease arrested the neurological progression of GM1
within a few months and resulted in a significantly prolonged
survival time.112 Further results showed that the eﬀect of NOEV
can be synergistically enhanced by co-administration with the
proteostasis regulators GM132 or celastrol.113
The strong inhibitory character of NOEV may endanger its
clinical eﬀectiveness by counterbalancing the b-Gal activity enhance-
ment in a dose-dependent manner. To cope with this problem,
Kuno and coworkers114 modified the structure of the lead chaper-
one and prepared new analogues, including 6-deoxy-NOEV (70;
Fig. 20) and a series of N-substituted (+)-conduramine derivatives
(71), which combined much weaker b-Gal inhibition potencies with
remarkable activity enhancements in fibroblasts from R201C GM1
patients. Compound 72, bearing an N-cyclohexylmethyl substituent,
exhibited the best chaperone (8.5-fold activity increase) versus
inhibitor (IC50 60 mM) ratio, although this result remains to be
validated in vivo (Fig. 20).
Computational analysis for prediction of molecular inter-
actions between the b-galactosidase protein and the chaperone
compound NOEV were first conducted using a homology
modeling method before the crystal structure of the protein
was available.115 The data pointed to the critical contribution to
complex stability of a hydrogen bonding between the amino
group and the catalytic glutamic acid residue Glu188. Such
interaction, which is similar to that further encountered for the
b-oriented anomeric hydroxyl of its catalytic product D-galactose
in the crystal structure of the corresponding complex with human
b-Gal (Fig. 21A), is absent in DGJ (Fig. 21B), which explains its
much weaker inhibition potency.116
Ortiz Mellet and coworkers117 conceived that the key hydrogen
bonding interaction with the catalytic acid E188 could be restored
in sp2-iminosugars having a bicyclic isothiourea-DGJ core, where
the protonated exocyclic nitrogen would act as a donor. At the
same time, a lipophilic substituent at this nitrogen can orient to
the same hydrophobic pocket hosting the octyl chain in the
NOEV:b-Gal complex. As a proof of concept, the 1-deoxygalacto-
nojirimycin analogue 6S-NBI-DGJ (73, Fig. 22) exhibited strong
and selective inhibition of b-Gal, with a ten-fold drop in aﬃnity
on going from pH 7 (IC50 3.1 mM) to pH 5 (IC50 32 mM).
Gratifyingly, 6S-NBI-DGJ induced b-Gal activity enhancements
comprised between 2- and 4-fold in fibroblasts from GM1
patients harboring the I51T/I51T, I51T/Y316C, I51T/R457Q,
G190D/G190D, R201C/R201C, G438E/G438E or R457Q/R457Q
mutations when used at 20–80 mM concentration.118 The only
exception was encountered for cells with the R59H homozygous
mutation. In a broader chaperone activity profiling on 88 types of
human b-Gal mutants transiently expressed in COS-7 cells, up to
24 mutants were responsive to 6S-NBI-DGJ treatment, the other
64 being unresponsive. Noticeably, the mutations with positive
responses included four common mutations, I51T, R201C, R208C,
and R482H, suggesting that 6S-NBI-DGJ would be beneficial as a
pharmacological chaperone for a large number of patients suffer-
ing from GM1-gangliosidosis. Therapeutic effects of 6S-NBI-DGJ in
the brain of the R201Cmodel mouse provided further evidence for
its potential clinical impact. Thus, oral administration of 6S-NBI-
DGJ at 5 and 10 mM significantly increased the mutant b-Gal
activity in lysates from the cerebral cortex and brain stem of R201C
Fig. 20 Structures of NOEV, 6-deoxy-NOEV and (+)-conduramine deriva-
tives developed as GM1 chaperones.
Fig. 21 Schematic representation of the H-bonding network (dotted lines)
of D-galactose (A) and DGJ (B) in the respective complexes with recombi-
nant human b-Gal. The presence and absence of the key interaction with
Glu188 is indicated with a green or red-crossed green arrow, respectively.
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mice and induced a remarkable reduction of lysosomal accumula-
tion of GM1 ganglioside in the cortical sections of treated mice.
The levels of autophagy-related proteins (LC3-II and p68) were also
significantly reduced. These data strongly suggest that 6S-NBI-DGJ
crossed the gastrointestinal and the blood–brain barriers and
attained the central nervous system where it enhanced the activity
of R201C mutant b-Gal and ameliorated the brain pathology.
A comparative analysis of GM1-associated b-Gal mutations
responsive to NOEV and to 6S-NBI-DGJ revealed significant
diﬀerences in their chaperone activity profiles.119 For instance,
NOEV was active as a chaperone for homozygous R201C but not
I51T b-Gal whereas 6S-NBI-DGJ enhanced the enzyme activity of
the two mutants in cell-based assays. The crystal structures
of the corresponding complexes with b-Gal showed analogous
hydrogen bonding networks at the catalytic site in both cases,
including the hypothesized hydrogen bonding between the
exocyclic nitrogen and E188, with the notable exception of the
interaction involving the hydroxymethyl substituent and Tyr133,
which is absent in the 6S-NBI-DGJ:b-Gal complex (Fig. 21). The
authors suggested that this scenario confers a higher adaptability
to the sp2-iminosugar chaperone that might be beneficial to
optimally fit in and stabilize proper folding of some mutant
forms of the enzyme.
Glycomimetic-based PCs for Fabry
disease
In 1995, Okumiya et al. reported that galactose restores
FD-associated mutant acid a-galactosidase (a-Gal A) activity.120
Subsequently, Fan et al. discovered that the iminosugar
glycomimetic 1-deoxygalactonojirimycin (DGJ, Fig. 19), a potent
inhibitor of a-Gal A (IC50 4 mM), restores the intracellular
activity of mutant a-Gal A in cultured lymphoblasts from
human hemizygous Fabry patients with the R301Q or Q279E
mutations.121 DGJ is approximately 120 000-fold more potent
than galactose as a chaperone. The enzyme activity increased
eight-fold or seven-fold (up to 48% or 45% of normal) after
cultivation of R301Q or Q279E lymphoblasts, respectively, with
DGJ at 20 mM for 4 days. However, DGJ at a concentration
higher than 20 mM nullified the enhancement eﬀect, high-
lighting the need of finely adjusting the dose to have an optimal
chaperone versus inhibitory eﬀect. The results were confirmed
in COS-7 cells transfected with human R301Q a-Gal A cDNA and
in fibroblasts of a transgenic mouse overexpressing human
R301Q a-Gal A. When administered orally to the R301Q trans-
genic mice at 0.5 mM concentration, up to 18-fold a-Gal A
activity increases were observed in the heart.
The above seminal work was followed by intense research
in the chaperoning potential of DGJ against a broad range of
disease-causing a-Gal A missense mutations in silico, in cellulo
and in vivo.122–128 DGJ was a-Gal A specific, and did not affect
misfolded mutant proteins in fibroblasts from other lysosomal
storage disease patients at the concentrations effective for a-Gal
A. Phase I clinical trials for DGJ (Amigalt) in healthy volunteers
for safety and pharmacokinetics as well as several Phase II clinical
trials with male and female Fabry patients who harboured a
variety of missense mutations have already been accom-
plished.129,130 A Phase III clinical trial for Amigalt in mono-
therapy is currently being conducted (data publication expected
in 2016; http://www.amicustherapeutics.com). Such treatment
(planned trade mark Galafolds) is expected to be highly
effective for patients who have missense mutations that pri-
marily lead to misfolding of the mutant protein (30% to 50% of
Fabry patients). The aggregation-associated loss of function
observed for the more severe a-Gal A mutants could be more
efficiently overturned by combining pharmacological chaper-
one treatment with the suppression of mutant enzyme aggrega-
tion, e.g. by the combined use of proteostatic regulators.131 DGJ
may also find efficacy in an adjunct therapy with manufactured
a-Gal A used in enzyme replacement therapy (ERT) for patients
whose residual enzyme activity cannot be increased by DGJ
alone to a level that reverses disease development (Phase 3
clinical trial ongoing; http://www.amicustherapeutics.com).
Thus, it was shown that coadministration of the chaperone
and the enzyme slows the denaturation and loss in activity of
a-Gal A ERT in vitro and increases uptake into cultured Fabry
patient-derived cells. Most importantly, the combined therapy
(DGJ orally administered, enzyme intravenously administered)
increases the circulating levels of active recombinant a-Gal A
used in enzyme replacement therapy in rodents and humans,
results in higher tissue a-Gal A levels in mice and Fabry patients
and leads to greater globotriaosylceramide (GL-3, Fig. 2) sub-
strate reduction in disease-relevant tissues of Fabry mice com-
pared to administration of a-Gal A in ERT alone.132,133 Similar
benefits were reported for an intravenously administered DGJ-
enzyme coformulation.134
Fig. 22 Schematic representation of the key H-bonding (dotted lines) and
van der Waals interactions (arcs) in the complexes of NOEV (orange) and
6S-NBI-DGJ (green) in the respective complexes with recombinant human
b-Gal. The catalytic glutamic acid residue E188, which is involved in the key
interaction with the protonated amino or imino group in NOEV and 6S-NBI-
DGJ is indicated with a blue arrow. The hydrogen bond implying the
hydroxymethyl group in NOEV and Tyr133, which is absent for 6S-NBI-DGJ,
is highlighted with a green or red-crossed green arrow, respectively.
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DGJ has monopolized research on pharmacological chaper-
ones for FD, with only a few alternative molecules on record.
Sakuraba and coworkers conducted a comparative study of the
chaperoning capabilities of DGJ and galactostatin bisulfite
(74, GBS; Fig. 23) in COS-7 cells expressing the human M51I
a-Gal A mutant.135 At 20 mM concentration both iminosugars
increased enzyme activity by about 2.5-fold. On the other hand,
the enzyme activity decreased when the concentration of the
iminosugars was increased to 100 mM although the amount of
protein remained the same, confirming that the iminosugars
act as both pharmacological chaperones and inhibitors for the
M51I mutant a-Gal A. SPR biosensor assaying further revealed
that the rate dissociation constant (kd) value of the mutant
a-Gal A:DGJ complex at pH 7.0 is almost the same as that at
pH 5.0, strongly suggesting that there is still room for chaper-
one improvement, i.e., modification of the chemical structure
for its quick dissociation from a mutant a-Gal A under acidic
pH conditions.135
Fleet, Kato and coworkers found that the enantiomer of DGJ,
L-DGJ (75; Fig. 23), behaved as a noncompetitive inhibitor of
a-Gal A (Ki 38.5 mM).
136 Treatment of R301Q FD fibroblasts
with 10 mM of L-DGJ increased intracellular a-Gal A activity by
10.8-fold, similar to that observed with 10 mM DGJ in a parallel
assay. Most interestingly, each enantiomer did not counteract
the chaperone eﬀect of the other enantiomer, showing
dose–response synergistic effects. In the pyrrolidine series,
2,5-dideoxy-2,5-imino-D-altritol (76, DIA; Fig. 23), a potent com-
petitive inhibitor of human a-Gal A (Ki 0.5 mM) isolated from the
roots of Adenophora triphylla, increased intracellular enzyme
activity by 9.6-fold in Fabry R301Q lymphoblasts when used at
500 mM concentration.137
The crystal structure of DGJ bound to human a-Gal A
revealed a hydrogen bonding interaction between the proto-
nated endocyclic amino group and the carboxylate group of the
catalytic aspartate nucleophile residue D170 that contributes
very significantly to the stability of the complex (Fig. 24A).138
It was postulated that protonation of D170 in the lysosome might
facilitate chaperone dissociation and substrate processing.139
Recent thermal shift assay experiments contradict this hypo-
thesis, however, supporting that DGJ binds a-Gal A with similar
aﬃnities at neutral and at acidic pH.140 The authors conclude
that DGJ is therefore not an optimal chaperone for Fabry disease,
which is consistent with the prevalence of the inhibitory char-
acter at concentrations over 20 mM. In the case of a neutral ligand
such as the monosaccharide galactose, the carboxylic acid cata-
lytic residue D231, opposite to D170, stabilizes the corresponding
complex by hydrogen bonding with the anomeric OH-1. Based on
this structural evidence, Higaki, Ortiz Mellet and coworkers
conceived that transformation of the basic amino group of DGJ
into a neutral arylthiourea functionality might lead to a new
family of a-Gal A inhibitors and chaperones, namely monocyclic
DGJ-arylthioureas (DGJ-ArTs), better suited for drug optimization
strategies (Fig. 24A).141 The strong hydrogen-bond donor capabi-
lities of the NH thiourea proton, exacerbated by the electron
withdrawing eﬀect of the aromatic substituent, would reinforce
the galactose-type complex stabilization mode.
The crystal structure of the complex between a-Gal and the
N0-p-fluorophenyl DGJ-ArT representative (77, DGJ-pFPhT) sup-
ported the above hypothesis. This compound and the N0-p-
methoxyphenyl analogue (78, DGJ-pMeOPhT) behaved as very
eﬃcient chaperones, promoting up to 7-fold enzyme activity
increases in Fabry disease fibroblasts expressing a-Gal A with the
Q279E or R301Q mutations as compared with untreated cells
when used at 30 mM, tripling the eﬀect of DGJ at its optimal
concentration of 20 mM. Immunofluorescence analyses revealed
that treatment of Q279E fibroblasts with DGJ-ArTs significantly
reduced the accumulation of globotriaosylceramide, indicating
that the rescued enzyme is actively processing the substrate at
the lysosome. To further investigate the chaperone eﬀect of
DGJ-ArTs on a range of mutant a-Gal A, a wild-type and 17 types of
missensemutants were transiently transfected into COS-7 cells, with
the activities of at least 15 out of the 17 mutants being significantly
enhanced. Additionally, DGJ-ArT chaperones were eﬃcient
at correcting impairment of autophagy, a well-established
hallmark of cellular pathology in lysosomal storage diseases.
Fig. 23 Structures of the piperidine iminosugars galactostatin bisulfate
(GBS) and L-DGJ and the pyrrolidine iminosugar DIA showing FD-associated
mutant a-Gal A chaperoning capabilities.
Fig. 24 (A) Schematic representation of the main H-bonding interactions
involving the catalytic acid aspartic acid residues in the complexes of DGJ,
D-galactose and DGJ-arylthiourea (DGJ-ArT) derivatives with human
a-Gal. (B) Structures of N0-p-fluorophenyl DGJ-ArT (77, DGJ-pFPhT) and
N0-p-methoxyphenyl DGJ-ArT (78, DGJ-pMeOPhT). (C) Synergetic eﬀect
of the combined treatment with the chaperone DGJ-pMeOPhT and the
proteostasis regulator 4-phenylbutiric acid (PBA) on SV-40-transformed
Q279E Fabry disease fibroblasts.
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Q279E FD fibroblasts were first transformed with simian virus-40
(SV-40) to avoid inconveniences derived from senescence and then
treated with the sp2-iminosugars. A significant reduction of the
levels of the autophagy-related proteins LC3-II and p62 was
observed. In addition, the DGJ-ArTs were found to act in a
synergetic manner with the proteostasis regulator 4-phenylbutiric
acid (4-PBA), confirming their potential in new Fabry disease
therapeutic strategies (Fig. 24B).141
Conclusions and future outlook
In 2001, only six years since the first report on the chaperoning
capabilities of galactose towards some FD-associated a-Gal A
mutants,120 Desnik and coworkers published the first success-
ful example of PC therapy in a patient: a 55-year-old man with
the cardiac variant of Fabry disease who had residual a-Gal A
activity as the result of a missense mutation (G328R) was given
a galactose infusion (1 g per kilogram over a four-hour period
every other day) and monitored for more than two years.142 At
the beginning of the treatment, the subject had severe myo-
cardial disease and was a candidate for cardiac transplantation.
Galactose-infusion treatment resulted in increased a-Gal A
activity (by 2- to 3-fold) in his circulating lymphocytes and
endomyocardial cells, which translated into improved cardiac
function. Cardiac transplantation was no longer required in this
patient and he could return to full-time work as a bus driver.
Deceivingly, after 20 years of intense research in the field, not a
single drug is available for LSD treatment based on the PC
concept. The files submitted to the FDA and EMA in 2016 by
Amicus Therapeutics Inc. on Galafolds (DGJ) for Fabry patients
harbouring responsive mutations might reverse this situation
and pave the way to other glycomimetic PC candidates.
Several hurdles can be identified that put at risk rapid
translation of PC therapies into the clinics. Some are intrinsic
to the neuronopathic character of most LSD conditions and the
diﬃculties for drugs to cross the blood–brain barrier.143 Tuning
PC amphiphilicity has been shown to allow reaching the central
nervous system, but relatively high PC doses were needed to
have a medically relevant result.118 Using targeted drug delivery
devices, a strategy currently under investigation for ERT,144 may
come in useful. Other limitations derive from the inability of
the current glycomimetic PCs to comply with all the require-
ments for efficient functional protein rescuing, such as the
need to program PCs to turn glucosidase binding from ‘‘on’’ at
the ER to ‘‘off’’ at the final destination. Dissociation of the
PC:glycosidase complex once in the lysosome is a prerequisite
to allow substrate processing and turnover.145 The high initial
substrate concentration in patient cells favors this exchange, but
further equilibration can uncover the inhibitory character of active
site-directed PCs, cancelling the chaperone benefit and thwarting
a medically relevant result. Ortiz Mellet, Garcı´a Ferna´ndez
and coworkers have recently proposed an original chaperone
prototype designed to undergo acid-promoted irreversible self-
inactivation after mutant enzyme enhancement.146 The authors
took advantage of the decisive contribution of hydrophobic
non-glycone interactions in the stability of complexes between
lysosomal glycosidases and sp2-iminosugar conjugates. Insertion
of an acid-labile orthoester moiety in the structure let switching
the nature of the chaperone from amphiphilic to hydrophilic in a
biologically useful pH window. At pH 7, in the ER, the compound
(e.g. 79) exhibits strong affinity for the target mutant enzyme,
being able to promote correct folding and facilitate trafficking.
Once at the lysosome at pH below 5, the orthoester group is
hydrolyzed, the hydrophobic segment is split off and the result-
ing hydrophilic derivative (e.g. 80) is no longer a ligand of the
enzyme and does not interfere with substrate processing. The
concept was applied to monocyclic DNJ (Fig. 25) and DGJ
sp2-iminosugar cores with high affinity towards human GCase
and a-Gal A, respectively. Immunodetection proved that no
inhibition effect occurred in fibroblasts of patients suffering
from Gaucher or Fabry disease even at concentrations up to
200 mM, manifesting a pure chaperone behavior.146
The development of more reliable methods to assess
chaperoning activity in situ, warranting that the measured enzyme
increases translates into significant activity enhancements and
substrate processing rates in the lysosomes, is contributing to
accelerate PC optimization strategies.147 In this sense, there is an
urgent need to establish protocols and initiatives for the reliable
comparison of glycomimetics from diﬀerent laboratories allowing
confident selection of the best leads for preclinical studies. The
contributions discussed in this Feature Article testify of the
vitality of the field; although to avoid undue lengthening we
have limited discussion to GD, GM1 and FD, glycomimetic-
based PC candidates have also been developed for several other
LSDs including Pompe,148 Krabbe,149 Tay-Sachs,150 Schindler/
Kanzaki151 or Sanfilippo diseases.152 The increasing awareness
that correction of lysosomal dysfunction might represent a
therapeutic strategy for other neurodegenerative diseases such
as Parkinson’s disease will likely stimulate research and open
new avenues for glycomimetic PCs.153 The coming years will
certainly witness significant progress in drug development
from the concerted eﬀorts of chemists, biochemists, structural
biologists and biomedical researchers.
Fig. 25 GCase inhibition plots for the orthoester-armed DGJ chaperone 79
at pH 7 (purple) and after incubation at pH 5 for 2 h (blue). HPLC monitoring
confirmed that full hydrolysis into the inactive hydrophilic product 80
occurred upon neutral-to-acidic pH switch.
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